anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
No evidence of carcinogenicity was seen in 1 mouse study or 2 rat studies following oral administration of Lamotrigine for up to 2 years at maximum tolerated doses (30 mg/kg/day for mice and 10 to 15 mg/kg/day for rats, doses that are equivalent to 90 mg/m2 and 60 to 90 mg/m2, respectively). Steady-state plasma concentrations ranged from 1 to 4 mcg/mL in the mouse study and 1 to 10 mcg/mL in the rat study. Plasma concentrations associated with the recommended human doses of 300 to 500 mg/day are generally in the range of 2 to 5 mcg/mL, but concentrations as high as 19 mcg/mL have been recorded.

Lamotrigine was not mutagenic in the presence or absence of metabolic activation when tested in 2 gene mutation assays (the Ames test and the in vitro mammalian mouse lymphoma assay). In 2 cytogenetic assays (the in vitro human lymphocyte assay and the in vivo rat bone marrow assay), Lamotrigine did not increase the incidence of structural or numerical chromosomal abnormalities.

No evidence of impairment of fertility was detected in rats given oral doses of Lamotrigine up to 2.4 times the highest usual human maintenance dose of 8.33 mg/kg/day or 0.4 times the human dose on a mg/m2 basis. The effect of Lamotrigine on human fertility is unknown.
A 10-week internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a stroke. In addition to the online program, a Guide with experience delivering ICBT will provide support by email or phone call once a week. The Guide will spend approximately 15 minutes per week/per client.
The purpose of the proposed pilot study is to evaluate a rehabilitative cognitive-behavioral group psychotherapy intervention and a telehealth intervention for veterans undergoing interferon treatment for the hepatitis C virus (HCV). The specific objectives of the proposed pilot study are: 1) develop study methods and materials; 2) evaluate study feasibility; and 3) assess the efficacy of a cognitive-behavioral group therapy approach and a telehealth approach as compared to care as usual in a randomized design. Participants will be 45 patients (15 participants in each condition) from the VA Boston Healthcare System who are undergoing interferon treatment for HCV. Assessment will occur at pre-treatment, post-treatment, and 3-month follow-up. Assessments will measure key areas, including adherence, quality of life, and psychological distress. Analyses will examine study feasibility and the effects of the treatment condition. It is hypothesized that the CBT condition and the telehealth condition will result in significantly improved outcomes, including enhanced adherence, quality of life, and psychological status. This treatment approach addresses initiatives by the National VHA Hepatitis C Program by optimizing the care of veterans experiencing the devastating side effects of interferon treatment.
The present invention provides a compound represented by formula (I) or a salt thereof, and a pest control agent, particularly an insecticide or acaricide, an ectoparasite control agent, or an endoparasite control agent or repellent, containing at least one selected from the group consisting of the compound represented by formula (I) and a salt thereof as an active ingredient. In the formula (I), R 1 And R 2 Each independently represents a hydrogen atom, a substituted or unsubstituted C1-6 alkyl group, or the like. Wherein R is 2 When it is a hydrogen atom, R 1 Is a substituted or unsubstituted C6-10 aryl group, or a substituted or unsubstituted 3-6 membered heterocyclic group. R 3 Represents a C1-6 alkylthio group or the like. R 4 And R 5 Each independently represents a hydrogen atom, a halogeno group or the like. Ar represents a substituted or unsubstituted C6-10 aryl group, or a substituted or unsubstituted aryl groupUnsubstituted 5-to 6-membered heteroaryl.
Neonatal hypoxic-ischemic encephalopathy after perinatal asphyxia causes neurolinguistic disturbances in children without disabilities. Poor academic performance appears as a long-term result. Language intervention is sought to reduce harmful effects on children. The aim of this study is showing the relationship between clinical conditions of hypoxic-ischemic-encephalopathy (HIE) and language disorders in children without disabilities. This cross-sectional study with a neurolinguistic approach was carried out in patients with perinatal asphyxia during childbirth, at the ZH Sikder Women's Medical College Hospital, Bangladesh. Respondents between 4 and 12 years, 76% underwent cranial computed tomography (CT); 82% underwent magnetic resonance imaging (MRI); and 70% underwent electroencephalogram (EEG). Among them were found positive results for neonatal hypoxia ischemic encephalopathy (EHI). These results are related to the following language disorders: reception/perception disorder (64%), sociolinguistic disorders (84%); metalinguistic competence disorder (66%); 86% of children had poor peer relationships and 72% had reading and writing disorders. Concluding, school-age children after perinatal asphyxia who developed Hypoxic-Ischemic Encephalopathy (HIE) had language disorders and poor school performance. There are still challenges to be overcome, as this is the first neurolinguistic approach in Bangladesh. More large-scale studies are needed.
It has been generally accepted that insulin resistance (IR) and reduced insulin secretory capacity are the basic pathogenesis of type 2 diabetes mellitus (T2DM). In addition to genetic factors, the persistence of systemic inflammation caused by obesity and the associated threat of lipotoxicity increase the risk of T2DM. In particular, the main cause of IR is obesity and subjects with T2DM have a higher body mass index (BMI) than normal subjects according to recent studies. The prevalence of T2DM with IR has increased with increasing BMI during the past three decades. According to recent studies, homeostatic model assessment of IR was increased compared to that of the 1990s. Rising prevalence of obesity in Korea have contributed to the development of IR, non-alcoholic fatty liver disease and T2DM and cutting this vicious cycle is important. My colleagues and I have investigated this pathogenic mechanism on this theme through clinical and experimental studies over 20 years and herein, I would like to summarize some of our studies with deep gratitude for receiving the prestigious 2023 Sulwon Award.
For patients who were not intubated, dexmedetomidine was infused at a rate of 0.1 microgram/kg per hour from study recruitment on the day of surgery until 8:00 am on the first day after surgery. For patients who were intubated and mechanically ventilated, dexmedetomidine infusion was started after the Richmond Agitation Sedation Scale was -2 or higher after intensive care unit admission until 8:00 am on the first day after surgery.
1. Technical Result Enhancement of medicinal properties. 2. Essence Use of a substituted triazolopyrimidine derivative of formula (1) (values R1, R2, R3, and R4 are provided in the description) and pharmaceutically acceptable salts thereof for treating of the growth of cancerous tumour cells and associated diseases or for inhibiting thereof in a mammals. 3. Field of Application Medicine.
The current proposal is a prospective, observational cohort study This study aims to determine the impact of structured weight loss (MOVE program) on GERD symptoms in overweight and obese veterans enrolled in a MOVE program. Successful weight loss will be defined as loss of 10% or higher baseline weight at 6 months follow up. Cases will be defined as subjects who achieved successful weight loss and controls as those who did not. GERD symptoms in subjects who lose weight (cases) will be compared to those with no weight loss (controls). Validated GERQ, RDQ and QOLRAD questionnaires will be used to assess prevalence of GERD symptoms, QOL and impact of weight loss on these symptoms. All MOVE participants will complete a validated GERQ, RDQ and QOLRAD questionnaires at baseline MOVE clinic visit and RDQ and QOLRAD during their follow up visits. Patient's total RDQ scores at baseline and follow up visits will be used to determine change in frequency and severity of GERD symptoms with weight loss, similarly change in the total QOLRAD questionnaire scores from baseline will be used to assess change in HRQOL with weight loss. Apart from information provided in MOVE!23, GERQ, RDQ and QOLRAD questionnaires, relevant information pertaining to obesity and GERD association will be obtained from patient's computerized medical records.

The impact of weight loss on GERD symptoms will be assessed. The impact of weight loss on QOL and GERD medication usage among MOVE participants will be assessed.
###  Risk Summary

Linezolid is present in breast milk. Based on data from available published case reports, the daily dose of linezolid that the infant would receive from breastmilk would be approximately 6% to 9% of the recommended therapeutic infant dose (10 mg/kg every 8 hours). There is no information on the effects of linezolid on the breastfed infant; however, diarrhea and vomiting were the most common adverse reactions reported in clinical trials in infants receiving linezolid therapeutically [see Adverse Reactions (6.1)] and (see Clinical Considerations). There is no information on the effects of linezolid on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for linezolid and any potential adverse effects on the breastfed child from linezolid or from the underlying maternal condition. 

###  Clinical Considerations

Advise lactating women to monitor a breastfed infant for diarrhea and vomiting.
PURPOSE:A cosmetic that contains volcanic mud occurring at the foot of Mt. Fuji, which is called TSURU soil or NARUSAWA soil, thus showing good emollient, skin-protecting, analgesic, recovering and warm-keeping effects and being used in foundation and make-up. CONSTITUTION:Volcanic mud such as TSURU soil or NARUSAWA soil obtained at the foot of Mt. FUJI, which may be directly used, however, preferably dried to a soil or ground into a fine powder of about 200 mesh pass, is added to give a cosmetic. The amount of the mud is about 0.5-100pts.wt. per 100pts.wt. of the cosmetic, especially 1-35pts.wt. in foundation, 8-50pts.wt. in make-up cosmetic, 40-100 in bath toilet, 4-15pts.wt. in soap and 25-60pts.wt. in tooth paste. When the mud is used in the form of suspension or emulsion, water is most suitable as matrix.
Enterally administrable diagnostic compositions for investigating alimentary functions comprise mul ple units of a size of at the most 5 mm, preferably between 0.5 and 1.3 mm, in particular between 0.7 and 1.0 mm, each uni- comprising a tracer-binding agent such as an ion exchange -ssin to which a radioactive tracer substance with a half-life of at the most 5 days, in particular <sup>99m</sup>Tc, <sup>113</sup>In, <sup>111</sup>In and <sup>129</sup>Cs, is associated, the tracer-binding agent being formulated with pharmaceutically acceptable excipients, in particular granulating excipients in such a way that the exposure of the gastrointestinal mucosa to the tracer-binding agent is reduced and that the units do not disintegrate during the passage through the gastrointestinal tract. Preferred units comprise cross-sectionally substantially homogeneous mutti-component cores in which the tracer-binding agent is granulated with one or more excipients and which are optionally coated.Preferred units comprise cross-sectionally substantially homogeneous multi-component cores made by granulating the tracer-binding agent with granulating excipients, the cores being coated with a diffusion coating. The labelling of the composition is performed at the site of use by immersing the units containing the tracer-binding agent in a solution of the tracer substance. The formulation of the tracer-binding agent with the excipients and the coating reduces leaching and permits easy variation of parameters important to the behaviour of the units in the gastrointestinal system such as size, density and surface properties. Tracer substances are normally present in an amount from about 2 to about 20% by weight, preferably from about 5 to about 10% by weight, calculated on the units. Due to low leaching and the non-disintegrating properties, the composition can be used to investiate gastric emptying also of the last 20% of a food bolus.
There is a need for scalable interventions to support the mental health and substance use challenges experienced by university students. One means of addressing this need is through the use of e-mental health tools that facilitate self-management and connect students to in-person supports as needed. This is a randomized controlled trial of a mobile app designed to help university students manage their mental health and substance use via a set of evidence-based tools that have been integrated into a single mobile app. The recruitment of approximately 1500 students will occur through social media, promotion by faculty members and administrators, and other in-person recruitment methods. Assessments will be conducted using self-report web surveys at baseline, 14 days (interim assessment) and 30 days (follow-up assessment). The goal of the trial is to assess the effectiveness of the app in improving a range of mental health and substance use outcomes of university students from baseline to follow-up.
Meiotic errors of relatively small chromosomes in oocytes result in egg aneuploidies that cause miscarriages and congenital diseases. Unlike somatic cells, which preferentially mis-segregate larger chromosomes, aged oocytes preferentially mis-segregate smaller chromosomes through unclear processes. Here, we provide a comprehensive three-dimensional chromosome identifying-and-tracking dataset throughout meiosis I in live mouse oocytes. This analysis reveals a prometaphase pathway that actively moves smaller chromosomes to the inner region of the metaphase plate. In the inner region, chromosomes are pulled by stronger bipolar microtubule forces, which facilitates premature chromosome separation, a major cause of segregation errors in aged oocytes. This study reveals a spatial pathway that facilitates aneuploidy of small chromosomes preferentially in aged eggs and implicates the role of the M phase in creating a chromosome size-based spatial arrangement.
The invention discloses a tegafur/layered double hydroxide (TF/LDHs) nanohybrid-magnetic matrix compound and a preparation method thereof. The preparation method utilizes LDHs as carriers to prepare the TF/LDHs nanohybrid-magnetic matrix compound. The TF/LDHs nanohybrid-magnetic matrix compound is used for targeted delivery and controlled release of tegafur, improves drug effects and reduces drug toxic and side effects. By a coprecipitation method, Fe3O4 or MgFe2O4 as a magnetic matrix is synthesized into the TF/LDHs nanohybrid-magnetic matrix compound which is a nano-complex composed of the magnetic matrix and TF intercalated LDHs coated on the magnetic matrix and is recorded as magnetic matrix @ (TF/LDHs). The TF/LDHs nanohybrid-magnetic matrix compound has strong magnetism and has good TF slow release effects. The preparation method has simple processes and allows mild reaction conditions. Through adjustment of magnetic matrix @ (TF/LDHs) nano-compound synthesis conditions and change of a drug concentration, a synthesis temperature, magnetic matrix content and applied magnetic field intensity, the structure, the composition and a release rate of the magnetic matrix @ (TF/LDHs) can be controlled.
FIELD: organic chemistry and technology. SUBSTANCE: 5-aminolevulinic acid hydrochloride is synthesized from 5-nitrolevulinic acid methyl ester by its catalytic hydrogenation on catalyst 5% Pd/C, at 5-30 C, under hydrogen pressure 10-20 at, in medium of lower alcohols, in the presence of hydrochloric acid. This method shows technological effectiveness, provides rather high yield of the end substance (up to 88.5%) of good quality (melting point at 147-149 C). Method is perspective for industrial-scale production. 5-Amino-levulinic acid is used for photodiagnosis and photodynamic therapy of malignant tumors of different localization and for treatment of patients with dermatosis of nontumor nature. Also, 5-aminolevulinic acid can be used as plant growth stimulating agent, herbicide and for other aims. EFFECT: improved method of synthesis, high yield, good quality. 1 tbl, 11 ex
FIELD: medicine, more particularly antidepressive duloxetine agent in the form of intestinal granules. SUBSTANCE: granule consists of nucleus comprising duloxetine and pharmaceutically acceptable filler, optionally separating layer, intestinal layer comprising hydroxypropylmethyl cellulose acetate-succinate and pharmaceutically acceptable filler, and optionally completing layer. Duloxetine granules are stable during storage period. Agent passes uncharged through stomach and rapidly separates out duloxetine in thin intestines. EFFECT: improved properties of the title granules. 10 cl, 11 ex
Participants will receive 15 minutes of taVNS after an initial 15 minute rest-period and a 15 minute baseline measurement period. For participants assigned to Intervention B, the pulse width = 300 μs, frequency = 25 Hz.
<P>PROBLEM TO BE SOLVED: To provide a clinical trial data management method and clinical trial data management system capable of obtaining a precise case report quickly by reducing time and labor as far as possible.  <P>SOLUTION: An information processor is connected to a pharmaceutical company, hospital, and a clinical trial data management center via a network. In the information processor, a person who owns an access right and its access content are different depending on the pharmaceutical company, the hospital, and the clinical trial data management center. A medical doctor at the hospital inputs clinical trial data to a picture created by the clinical trial data management center in the information processor connected to the network. The pharmaceutical company looks at the clinical trial data in the picture created by the clinical trial data management center and can comment on (or enquire about) the clinical trial data. The medical doctor looks at the comment, corrects the clinical trial data if necessary, and describes his or her reason for the correction. The pharmaceutical company fixes the clinical trial data returned from the hospital and outputs the data on the clinical trial.  <P>COPYRIGHT: (C)2007,JPO&INPIT
FIELD: medicine. SUBSTANCE: method involves removal of necrotic foci from the pancreas surface using a jet injector. A jet of physiological saline solution is applied from a 7-8 cm distance between the nozzle and the tissue surface. Two or three parallel longitudinal cuts are made to enhance the outflow of ferments of the pancreas. A cold solution (5 C) applied after making the cuts contains Novocain, inhibitors of ferments, and antibiotic agents. EFFECT: optimal conditions for decompression and drainage of pancreas; inhibited destructive processes; less traumatic treatment; higher quality of removal of necrotic tissue.
This study aimed to develop a propellant-free topical spray formulation of Etodolac (BCS-II), a potent NSAID, which could be beneficial in the medical field for the effective treatment of pain and inflammation conditions. The developed novel propellant-free spray formulation is user-friendly, cost-effective, propellant-free, eco-friendly, enhances the penetration of Etodolac through the skin, and has a quick onset of action. Various formulations were developed by adjusting the concentrations of different components, including lecithin, buffering agents, film-forming agents, plasticizers, and permeation enhancers. The prepared propellant-free spray formulations were then extensively characterized and evaluated through various in vitro, ex vivo, and in vivo parameters. The optimized formulation exhibits an average shot weight of 0.24 ± 0.30 ml and an average drug content or content uniformity of 87.3 ± 1.01% per spray. Additionally, the optimized formulation exhibits an evaporation time of 3 ± 0.24 min. The skin permeation study demonstrated that the permeability coefficients of the optimized spray formulation were 21.42 cm/h for rat skin, 13.64 cm/h for mice skin, and 18.97 cm/h for the Strat-M membrane. When assessing its potential for drug deposition using rat skin, mice skin, and the Strat-M membrane, the enhancement ratios for the optimized formulation were 1.88, 2.46, and 1.92, respectively against pure drug solution. The findings from our study suggest that the propellant-free Etodolac spray is a reliable and safe topical formulation. It demonstrates enhanced skin deposition, and improved effectiveness, and is free from any skin irritation concerns.
There are up to 5 planned dose levels, with 3 de-escalation dose levels available in case dose level 1 is determined to exceed the MTD. This arm will enroll 15-30 subjects if all dose levels are explored.
In general, the use of clonazepam in women of childbearing potential, and more specifically during known pregnancy, should be considered only when the clinical situation warrants the risk to the fetus.

The specific considerations addressed above regarding the use of anticonvulsants for epilepsy in women of childbearing potential should be weighed in treating or counseling these women.

Because of experience with other members of the benzodiazepine class, clonazepam is assumed to be capable of causing an increased risk of congenital abnormalities when administered to a pregnant woman during the first trimester. Because use of these drugs is rarely a matter of urgency in the treatment of panic disorder, their use during the first trimester should almost always be avoided. The possibility that a woman of childbearing potential may be pregnant at the time of institution of therapy should be considered. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Patients should also be advised that if they become pregnant during therapy or intend to become pregnant, they should communicate with their physician about the desirability of discontinuing the drug.
Despite the large impact chronic obstructive pulmonary disease (COPD) that has on the population, the implementation of new technologies for diagnosis and treatment remains limited. Current practices in ambulatory oxygen therapy used in COPD rely on fixed doses overlooking the diverse activities which patients engage in. To address this challenge, we propose a software architecture aimed at delivering patient-personalized edge-based artificial intelligence (AI)-assisted models that are built upon data collected from patients' previous experiences along with an evaluation function. The main objectives reside in proactively administering precise oxygen dosages in real time to the patient (the edge), leveraging individual patient data, previous experiences, and actual activity levels, thereby representing a substantial advancement over conventional oxygen dosing. Through a pilot test using vital sign data from a cohort of five patients, the limitations of a one-size-fits-all approach are demonstrated, thus highlighting the need for personalized treatment strategies. This study underscores the importance of adopting advanced technological approaches for ambulatory oxygen therapy.